ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

11:30AM-1:00PM: Abstract Number: 0935

Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE

Plenary Session II (0934–0939)

11:30AM-1:00PM: Abstract Number: 0937

Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study

Plenary Session II (0934–0939)

11:30AM-1:00PM: Abstract Number: 0938

Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity

Plenary Session II (0934–0939)

11:30AM-1:00PM: Abstract Number: 0939

Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial

Plenary Session II (0934–0939)

11:30AM-1:00PM: Abstract Number: 0936

Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis

Plenary Session II (0934–0939)

11:30AM-1:00PM: Abstract Number: 0934

Warfarin Use and Risk of Knee and Hip Replacements

Plenary Session II (0934–0939)

3:00PM-3:50PM: Abstract Number: 0986

BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus

SLE – Treatment (0985–0989)

3:00PM-3:50PM: Abstract Number: 0978

Border-associated Macrophages Drive Recruitment of Immune Cells into the Choroid Plexus in Mice with Neuropsychiatric Lupus

SLE – Animal Models (0975–0979)

3:00PM-3:50PM: Abstract Number: 0985

Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies

SLE – Treatment (0985–0989)

3:00PM-3:50PM: Abstract Number: 0987

Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study

SLE – Treatment (0985–0989)

3:00PM-3:50PM: Abstract Number: 0977

Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells

SLE – Animal Models (0975–0979)

3:00PM-3:50PM: Abstract Number: 0975

Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage

SLE – Animal Models (0975–0979)

3:00PM-3:50PM: Abstract Number: 0976

Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion

SLE – Animal Models (0975–0979)

3:00PM-3:50PM: Abstract Number: 0972

Mapping Oligoclonally Expanded T Cells Within the Peripheral and Synovial Immune Landscape of Untreated ACPA+ Rheumatoid Arthritis Patients at the Single Cell Level

RA – Etiology & Pathogenesis (0970–0974)

3:00PM-3:50PM: Abstract Number: 0973

Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis

RA – Etiology & Pathogenesis (0970–0974)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].